Mo1790 Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
Walter Reinisch(Medical University of Vienna), Dino Tarabar(Military Medical Academy), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Lakshmi Padgett(Janssen (United States)), Paul Rutgeerts(KU Leuven), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Judith Collins(Oregon Health & Science University), Rick Strauss, Jewel Johanns(Johnson & Johnson (United States)), Omoniyi J. Adedokun(Western University), Hongyan Zhang(Northwest A&F University), William J. Sandborn(University of San Diego)
Cited by 1
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k